Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

 

 

ARTICLE 12 TERM AND TERMINATION 65
     
  12.1 Term and Expiration. 65
  12.2 Termination. 66
  12.3 Rights in Bankruptcy. 67
  12.4 Consequences of Termination. 67
  12.5 Remedies. 68
  12.6 Accrued Rights; Surviving Obligations. 68
     
ARTICLE 13 MISCELLANEOUS 69
     
  13.1 Force Majeure. 69
  13.2 Export Control. 70
  13.3 Assignment. 70
  13.4 Severability. 71
  13.5 Dispute Resolution. 71
  13.6 Governing Law. 72
  13.7 Notices. 73
  13.8 Entire Agreement; Amendments. 73
  13.9 English Language. 73
  13.1 Equitable Relief. 74
  13.11 Waiver and Non-Exclusion of Remedies. 74
  13.12 No Benefit to Third Parties. 74
  13.13 Further Assurance. 74
  13.14 Relationship of the Parties. 75
  13.15 HSR Act Compliance 75
  13.16 References. 75
  13.17 Construction. 76
  13.18 Counterparts. 76

 

SCHEDULES

 

Schedule 1.65 Licensed Compounds
Schedule 1.93 Second Category Indications
Schedule 3.1.2(i) Development Plan
Schedule 3.1.2(ii) Lilly Pre-Clinical Activities
Schedule 9.6 Press Releases
Schedule 10.2.2 Existing Patents

 

 


© AC Immune 2015